Viking Therapeutics Shares Plummet Following Clinical Trial Data Release

Viking Therapeutics US92686J1060

Shares of Viking Therapeutics experienced a dramatic sell-off after the biopharmaceutical company released Phase 2 trial results for its oral weight-loss drug candidate, VK2735. The stock plummeted approximately 34% as investors digested the complex data set.

While the study demonstrated impressive efficacy—with the highest dose group achieving an average weight reduction of 12.2% in just 13 weeks—concerns over patient discontinuation rates and gastrointestinal side effects overshadowed these positive results. This adverse reaction prompted a significant market reassessment of the drug’s commercial potential.

Key Trial Outcomes and Market Context